Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Carfilzomib and Dexamethasone in Combination With Cyclophosphamide vs. Carfilzomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: a Phase II Randomized Controlled Trial

NCT03336073 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT03336073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03336073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Carfilzomib and Dexamethasone in Combination With Cyclophosphamide vs. Carfilzomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: a Phase II Randomized Controlled Trial
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Unknown status
Start date
December 18, 2017
Completion date
December 31, 2024
Enrollment
199 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma